OBJECTIVES Acute sinusitis is a common upper respiratory tract infection worldwide, which can be severely complicated if inappropriate treatment is applied. The aim of this study was to assess and compare efficacy of cefuroxime and co-amoxiclav in the treatment of acute sinusitis in an Iranian sample population. METHODS A randomized clinical trial, comparing the efficacy of two oral antibioti...

BACKGROUND The ORACLE II trial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of placebo for women in spontaneous preterm labour and intact membranes, without overt signs of clinical infection, by use of a factorial randomised design. The aim of the present study--the ORACLE Children Study II--was to determine the long-term effects on children after exp...

Between 1994 and 1996 we detected 28 out of 7054 (0.4%) clinical isolates of Escherichia coli with abnormal or reduced inhibition diameters to co-amoxiclav and ceftazidime in a disc diffusion test. The increased MIC of ceftazidime (1-32 mg/L) and the effect of synergy between this antibiotic and co-amoxiclav according to the disc diffusion test suggest the presence of an extended-spectrum beta-...

The effect on the nasopharyngeal bacterial flora of therapy for 10 days with co-amoxiclav or cefprozil was studied in 50 children with acute otitis media. Before therapy, potential pathogens (Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis) were isolated in 14 (56%) of those treated with co-amoxiclav and 15 (60%) of those treated with cefprozil. Following therapy, the...

In vitro susceptibility data were collected for co-amoxiclav and other antimicrobial agents against 1297 recent anaerobe isolates collected in Europe and the USA. The co-amoxiclav (amoxicillin/clavulanic acid) MIC(50/90)s (amoxicillin/clavulanic acid concentration in a ratio of 2:1, expressed in terms of amoxicillin concentration in mg/L) were 0.5/4 for Bacteroides fragilis, </=0.125/1 for Prev...

Mean fecal global yeast counts increased similarly during 7 days of treatment with telithromycin (800 mg once daily) or amoxicillin-clavulanic acid (amoxiclav) (1 g of amoxicillin and 125 mg of clavulanic acid 3 times daily) in human volunteers and decreased slowly thereafter. On skin, coagulase-negative staphylococci of decreased susceptibility (DS) to telithromycin increased in the telithromy...

SUMMARY OBJECTIVES To compare the efficacy of co-amoxiclav (amoxicillin + clavulanic acid) and the triple therapy of ampicillin + gentamycin + metronidazole as prophylactic antibiotic during Caesarean sections. DESIGN A randomized controlled trial. SETTING The study was conducted between March and December 2002 at Komfo Anokye Teaching Hospital, Kumasi. PARTICIPANTS Patients undergoing ca...

A 3-day regimen of azithromycin (500 mg once daily) and a 10-day regimen of co-amoxiclav (625 mg three times daily) were compared in a double-blind study of 67 patients with acute infectious exacerbations of chronic bronchitis (AIECBs, n = 54), acute bronchitis (n = 7), or pneumonia (n = 6). In patients treated with azithromycin, satisfactory clinical responses (cure or improvement) were seen i...

Background Co-amoxiclav, a combination antibiotic consisting of amoxicillin and clavulanic acid, is one of the most commonly prescribed anti-microbial drugs. Unfortunately, human exposure is associated with liver injury and in rare cases, acute liver failure has been reported. The risk of liver injury appears be higher when amoxicillin/clavulanic acid is used in combination. Little is known abo...

The first case of infective discitis caused by Eikenella corrodens in an adolescent is presented. The need for anaerobic cultures when dealing with infective pathology in the spine is stressed. A 14 year old boy presented with acute exacerbation of back pain, which showed characteristics of infective discitis after magnetic resonance imaging. Computed tomography guided biopsy grew E corrodens i...